Form 424B4 - Prospectus [Rule 424(b)(4)]:
SEC Accession No. 0001104659-24-092246
Filing Date
2024-08-23
Accepted
2024-08-23 08:30:32
Documents
6

Document Format Files

Seq Description Document Type Size
1 424B4 tm2413457-9_424b4.htm 424B4 943688
2 GRAPHIC lg_evaxionaiimmunology-bwlr.jpg GRAPHIC 10983
3 GRAPHIC tb_stageofdev-4clr.jpg GRAPHIC 82669
4 GRAPHIC tb_screeningpembro-4clr.jpg GRAPHIC 31981
5 GRAPHIC tb_treatmentgroups-4clr.jpg GRAPHIC 43283
6 GRAPHIC bc_ngstrains-4clr.jpg GRAPHIC 61843
  Complete submission text file 0001104659-24-092246.txt   1258404
Mailing Address DR NEERGAARDS VEJ 5F HOERSHOLM G7 2970
Business Address DR NEERGAARDS VEJ 5F HOERSHOLM G7 2970 004531262615
Evaxion Biotech A/S (Filer) CIK: 0001828253 (see all company filings)

EIN.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: 424B4 | Act: 33 | File No.: 333-279153 | Film No.: 241233568
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)